Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Sartorius Stedim Biotech: Dynamic First Quarter in 2015 | Forecast Revised Upwards

04/14/2015 | 02:26pm EDT

Regulatory News:

Sartorius Stedim Biotech (Paris:DIM), a leading supplier for the biopharmaceutical industry, today pre-announced results for the first quarter 2015. Based on preliminary figures sales revenue grew around 22% in constant currencies to approximately €204 million (reported gain: around 33%).

Due to the low prior-year revenue base, the company had expected above-average growth rates for this first quarter. Nevertheless, the gains supported by strong performance in all product segments were higher than projected at the beginning of the year.

Based on the results of the first three months, Sartorius Stedim Biotech has revised its forecast upwards for the full year of 2015. Sales revenue in constant currencies is now expected to increase approximately 7% to 10% (previous guidance: approx. 4% to 7%). Management projects that the company‘s underlying EBITDA margin in constant currencies will reach around 24.5% to 25% (previous guidance: around 24.0% to 24.5%).

Further information will be published on April 20, 2015.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge products and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.


© Business Wire 2015
Latest news "Companies"
09:12aASTRAZENECA : Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
PU
09:07aSHANGHAI ELECTRIC : Ranks 51st on ENR's 2021 Top 250 International Contractors List
AQ
09:07aDAIICHI SANKYO : ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
BU
09:07aASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
BU
09:06aMERCK : KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
BU
09:06aMERCK : KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
BU
09:02aWINTRUST FINANCIAL : Follow These 5 Steps To Make Changing Banks Easier
PU
09:02aESMO CONGRESS 2021 : Efficacy and Safety of Poziotinib in Treatment-naïve NSCLC Harboring HER2 exon 20 Mutations: A Multinational Phase 2 Study (ZENITH20-4)
PU
09:00aUK business minister meets energy bosses over soaring gas prices
RE
08:46aSPECTRUM PHARMACEUTICALS : Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021
BU
Latest news "Companies"